Solid Biosciences Inc.
Σύμβολο: SLDB
NASDAQ
10.23
USDΤιμή αγοράς σήμερα
-2.2174
Λόγος P/E
0.0499
Δείκτης PEG
386.25M
MRK Cap
- 0.00%
DIV Απόδοση
Solid Biosciences Inc. (SLDB) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 612.23 | 123.6 | 213.7 | 207.8 | |||||||||
balance-sheet.row.short-term-investments | 232.96 | 49.6 | 58.3 | 88.6 | |||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 6 | |||||||||
balance-sheet.row.other-current-assets | 14.25 | 6.1 | 5.9 | 8.7 | |||||||||
balance-sheet.row.total-current-assets | 636.16 | 129.7 | 219.6 | 222.6 | |||||||||
balance-sheet.row.property-plant-equipment-net | 139.54 | 33.2 | 38.6 | 7.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 7.33 | 1.8 | 1.8 | 2.1 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 0.94 | 0.2 | 0.2 | 0.1 | |||||||||
balance-sheet.row.total-non-current-assets | 147.82 | 35.2 | 40.6 | 9.8 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.account-payables | 12.49 | 2 | 3.2 | 4.5 | |||||||||
balance-sheet.row.short-term-debt | 9.14 | 2.3 | 2.6 | 1.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 99.13 | 23.9 | 26 | 0.6 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 22.88 | 10.2 | 16.7 | 9.6 | |||||||||
balance-sheet.row.total-non-current-liabilities | 99.13 | 23.9 | 26.1 | 0.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 105.95 | 23.9 | 28.5 | 2.1 | |||||||||
balance-sheet.row.total-liab | 165.62 | 38.5 | 48.6 | 24.2 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 0.08 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.retained-earnings | -2507.41 | -658.8 | -562.7 | -476.8 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.04 | 0 | -0.1 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 3125.66 | 785.2 | 774.5 | 684.9 | |||||||||
balance-sheet.row.total-stockholders-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 783.98 | - | - | - | |||||||||
Total Investments | 234.79 | 51.5 | 58.3 | 88.6 | |||||||||
balance-sheet.row.total-debt | 108.27 | 26.3 | 28.5 | 2.1 | |||||||||
balance-sheet.row.net-debt | -271 | -47.8 | -126.8 | -117.1 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -96.02 | -96 | -86 | -72.2 | |||||||||
cash-flows.row.depreciation-and-amortization | 2.96 | 2.6 | 2.4 | 3 | |||||||||
cash-flows.row.deferred-income-tax | -46.06 | -13.6 | 0 | 1.2 | |||||||||
cash-flows.row.stock-based-compensation | 7.63 | 7.6 | 7.5 | 13.4 | |||||||||
cash-flows.row.change-in-working-capital | -6.34 | -6.3 | -3.7 | -23 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.1 | -0.1 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | -11.5 | |||||||||
cash-flows.row.account-payables | -0.76 | -0.8 | -5.2 | 1.2 | |||||||||
cash-flows.row.other-working-capital | -4.67 | -5.6 | 1.4 | -12.6 | |||||||||
cash-flows.row.other-non-cash-items | 43.65 | 11.5 | -18.3 | -0.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -94.18 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.acquisitions-net | 26.56 | -9.7 | 31.5 | 89.8 | |||||||||
cash-flows.row.purchases-of-investments | -117.43 | -117.4 | -182.8 | -141.2 | |||||||||
cash-flows.row.sales-maturities-of-investments | 128.63 | 128.6 | 212.8 | 51.4 | |||||||||
cash-flows.row.other-investing-activites | 11.2 | 9.7 | 0.6 | -89.8 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 9.69 | 9.7 | 59.2 | -91.1 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||||
cash-flows.row.common-stock-issued | 5.51 | 3 | 72.6 | 134.9 | |||||||||
cash-flows.row.common-stock-repurchased | 0.16 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | -5.16 | 0.1 | 2.3 | 0.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.74 | 3.1 | 74.8 | 135 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 76.19 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -81.37 | -81.4 | 36 | -33.9 | |||||||||
cash-flows.row.cash-at-end-of-period | 384.77 | 74 | 157.2 | 121.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 466.14 | 155.4 | 121.2 | 155.1 | |||||||||
cash-flows.row.operating-cash-flow | -94.18 | -94.2 | -98 | -77.8 | |||||||||
cash-flows.row.capital-expenditure | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.free-cash-flow | -95.69 | -95.7 | -101 | -79 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 8.1 | 13.6 | |||||||||
income-statement-row.row.cost-of-revenue | 2.96 | 2.6 | 2.4 | 58.7 | |||||||||
income-statement-row.row.gross-profit | -2.96 | -2.6 | 5.7 | -45.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 76.56 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 27.75 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.operating-expenses | 103.73 | 101.7 | 107.4 | 85.9 | |||||||||
income-statement-row.row.cost-and-expenses | 104.31 | 104.3 | 107.4 | 85.9 | |||||||||
income-statement-row.row.interest-income | 7.14 | 7.1 | 2.6 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 2.96 | 2.6 | -1.5 | 3 | |||||||||
income-statement-row.row.ebitda-caps | -102.01 | - | - | - | |||||||||
income-statement-row.row.operating-income | -104.25 | -104.3 | -106.5 | -72.3 | |||||||||
income-statement-row.row.income-before-tax | -96.02 | -96 | -86 | -72.2 | |||||||||
income-statement-row.row.income-tax-expense | -4.56 | 0 | -20.5 | -0.1 | |||||||||
income-statement-row.row.net-income | -94.06 | -96 | -65.5 | -72.1 |
Συχνές ερωτήσεις
Ποιο είναι το Solid Biosciences Inc. (SLDB) το σύνολο του ενεργητικού?
Solid Biosciences Inc. (SLDB) το συνολικό ενεργητικό είναι 164939000.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι N/A.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.000.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι -4.694.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι 0.000.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι 0.000.
Ποια είναι η Solid Biosciences Inc. (SLDB) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι -96015000.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 26265000.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 101734000.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι 74015000.000.